You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Belantamab Mafodotin, Cyclophosphamide and Dexamethasone
  • (no location specified)
2021-10-08
Oct 8, 2021
M
Active, not recruiting
  • Multiple Myeloma
  • Charlotte, North Carolina
    Levine Cancer Institute
2021-11-23
Nov 23, 2021
Z
Terminated
  • Relapsed/Refractory Multiple Myeloma(MM)
  • CART therapy in Relapsed/Refractory multiple myeloma
  • Guangdong, Guangdong, China
    Southern Medical University Zhujiang Hospital
2021-09-17
Sep 17, 2021
M
Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Louisville, Kentucky
  • +1 more
2021-12-12
Dec 12, 2021
W
Active, not recruiting
  • Relapsed/Refractory Multiple Myeloma
  • LCAR-BCX cells product
  • Shanghai, China
    Shanghai Changzheng Hospital
2021-11-01
Nov 1, 2021
E
Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  • Boston, Massachusetts
  • +2 more
2021-12-16
Dec 16, 2021
C
Recruiting
  • Multiple Myeloma
  • Relapse Multiple Myeloma
  • Bethesda, Maryland
  • +1 more
2021-12-02
Dec 2, 2021
T
No longer available
  • Multiple Myeloma
  • Winston-Salem, North Carolina
    Wake Forest
2021-09-16
Sep 16, 2021
C
Recruiting
  • Multiple Myeloma
  • +2 more
  • BCMA targeted prime CAR-T cells
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force
2021-07-30
Jul 30, 2021
C
Recruiting
  • Multiple Myeloma
  • +2 more
  • BCMA CAR-T cells
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force
2021-03-01
Mar 1, 2021
U
Recruiting
  • Multiple Myeloma in Relapse
  • Aurora, Colorado
    University of Colorado Hospital
2021-12-30
Dec 30, 2021
C
Enrolling by invitation
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • C-4-29 Cells
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
2021-08-02
Aug 2, 2021
C
Recruiting
  • Multiple Myeloma
  • +2 more
  • BCMA CAR-T cells
  • Chongqing, Chongqing, China
    Chongqing University Cancer Hospital
2021-03-01
Mar 1, 2021
C
Active, not recruiting
  • Multiple Myeloma
  • New York, New York
  • +1 more
2021-05-05
May 5, 2021
T
Recruiting
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Rapid Infusion Isatuximab
  • San Francisco, California
    University of California San Francisco
2021-05-28
May 28, 2021
H
Recruiting
  • Multiple Myeloma
  • Anti-BCMA CAR-T cells
  • +3 more
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
2021-08-29
Aug 29, 2021
A
Active, not recruiting
  • Relapsed/Refractory Multiple Myeloma
  • ALLO-605
  • +3 more
  • Denver, Colorado
  • +3 more
2021-10-13
Oct 13, 2021
N
Active, not recruiting
  • Multiple Myeloma
  • Oslo, Norway
  • +1 more
2021-11-04
Nov 4, 2021
U
Not yet recruiting
  • Multiple Myeloma
  • SLAMF7 BATs
  • Charlottesville, Virginia
    University of Virginia
2021-04-27
Apr 27, 2021
B
Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • BGB-11417 + Dexamethasone
  • BGB-11417 + Dexamethasone + Carfilzomib
  • Fitzroy, Australia
  • +1 more
2021-09-27
Sep 27, 2021
C
Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • UCARTCS1A
  • San Francisco, California
  • +4 more
2021-11-11
Nov 11, 2021
P
Not yet recruiting
  • Multiple Myeloma
  • Refractory Multiple Myeloma
  • Digital Health Coaching Program
  • Fitbit
  • (no location specified)
2022-01-05
Jan 5, 2022
U
Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • La Jolla, California
    UCSD Moores Cancer Center
2020-12-02
Dec 2, 2020
G
Recruiting
  • Multiple Myeloma, Refractory
  • +2 more
  • TEG002
  • Boston, Massachusetts
  • +2 more
2021-07-09
Jul 9, 2021